Arcutis outlines $535M-$545M 2026 net revenue guidance while preparing for February 23, 2027 infant AD PDUFA (NASDAQ:ARQT)
Arcutis Biotherapeutics (ARQT) reported Q3 2026 net product revenues of $143.9M, citing strong sales and demand growth. The company outlined 2026 net revenue guidance of $535M-$545M and is preparing for a February 23, 2027 PDUFA date for its infant AD treatment, according to CEO Todd Watanabe.
How this was made
The 30-second read
Why it matters
The guidance range of $535M-$545M is a key data point for valuation models.
Market read
New revenue guidance is material for traders and may drive short-term price movement.
What to watch
Potential upcoming regulatory approvals or pipeline milestones not mentioned.
Background
Arcutis Biotherapeutics (NASDAQ:ARQT) reported Q3 product revenue and provided 2026 guidance.
Ticker impact
Arcutis disclosed Q3 net product revenues of $143.9M and set 2026 net revenue guidance of $535M-$545M.
potential downside as investors price in lower revenue outlook
New guidance numbers are material and were not previously public, likely prompting a sell pressure.
Market effects
Biotech sector may see broader sentiment shift if guidance trends repeat.
US biotech investors likely adjust positions.
Limited to firms with similar product pipelines.
Counterpoint
Guidance could be a buying opportunity if the market overreacts to short-term numbers.
Key entities
- companyArcutis Biotherapeutics
Biopharma developing dermatology treatments.

